These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19154240)

  • 21. A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses.
    Kelly AC; Sheitman BB; Hamer RM; Rhyne DC; Reed RM; Graham KA; Rau SW; Gilmore JH; Perkins DO; Peebles SS; VanderZwaag CJ; Jarskog LF
    J Clin Psychopharmacol; 2014 Aug; 34(4):441-5. PubMed ID: 24943389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight change after an atypical antipsychotic switch.
    Ried LD; Renner BT; Bengtson MA; Wilcox BM; Acholonu WW
    Ann Pharmacother; 2003 Oct; 37(10):1381-6. PubMed ID: 14519048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Consensus development conference on antipsychotic drugs and obesity and diabetes.
    ; ; ;
    J Clin Psychiatry; 2004 Feb; 65(2):267-72. PubMed ID: 15003083
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents.
    Henderson DC
    J Clin Psychiatry; 2001; 62 Suppl 27():10-4; discussion 40-1. PubMed ID: 11806484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
    Lindenmayer JP; Tedeschi F; Yusim A; Khan A; Kaushik S; Smith RC; Parakadavil M
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):185-92. PubMed ID: 22182455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study.
    Burns T; Christova L; Cooper S; Harrison G; McKendrick J; Laugharne R; Obuaya T; McCreadie R; O'Brien S; Perrington S; Stephenson D
    Acta Psychiatr Scand; 2006 Feb; 113(2):126-34. PubMed ID: 16423164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategies for transitioning therapy to aripiprazole from other antipsychotics in schizophrenia.
    Wisniewski CS; Robert S
    Ann Pharmacother; 2012; 46(7-8):1097-104. PubMed ID: 22811346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Borlido C; Remington G; Graff-Guerrero A; Arenovich T; Hazra M; Wong A; Daskalakis ZJ; Mamo DC
    J Clin Psychiatry; 2016 Jan; 77(1):e14-20. PubMed ID: 26845273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The art and science of switching of antipsychotic medications, part 1.
    Weiden PJ; Young AH; Buckley PF
    J Clin Psychiatry; 2006 Nov; 67(11):e15. PubMed ID: 17201045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
    Vera-Llonch M; Delea TE; Richardson E; Rupnow M; Grogg A; Oster G
    Value Health; 2004; 7(5):569-84. PubMed ID: 15367252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
    Weiden PJ; Daniel DG; Simpson G; Romano SJ
    J Clin Psychopharmacol; 2003 Dec; 23(6):595-600. PubMed ID: 14624190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness.
    Megna JL; Kunwar AR; Mahlotra K; Sauro MD; Devitt PJ; Rashid A
    J Psychiatr Pract; 2007 Mar; 13(2):129-37. PubMed ID: 17414692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
    Fleischhacker WW; Siu CO; Bodén R; Pappadopulos E; Karayal ON; Kahn RS;
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):987-95. PubMed ID: 23253821
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.
    Meyer JM; Pandina G; Bossie CA; Turkoz I; Greenspan A
    Clin Ther; 2005 Dec; 27(12):1930-41. PubMed ID: 16507379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors.
    Barnett M; Argo T; Alexander B; Perry P
    Ann Clin Psychiatry; 2006; 18(1):1-7. PubMed ID: 16517447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.